Democrats Sold Out the American Dream - Are you ready?

There's a massive housing crisis looming, and nobody on Main Street knows it yet... The Democrats sold out the American Dream - and now, millions of Americans are locked out of the housing market, forced to become "permanent renters."

Click here to see exactly what you need to do >>>

Pankaj Mohan Biography and Net Worth

CEO of Sonnet BioTherapeutics

Dr. Pankaj Mohan founded Sonnet in 2015 and currently serves as Chief Executive Officer and Chairman. He is also a member of the Board of Directors of Outlook Therapeutics, Inc. which he also founded (formerly known as Oncobiologics). From January 2011 to June 2018, he served as Oncobiologics’ President, Chief Executive Officer, and Chairman. Previously, Dr. Mohan served as head of Business Operations and Portfolio Management of Biologics Process and Product Development at Bristol-Myers Squibb Company and as a Director of Bioprocess Engineering at Genentech, Inc. Prior to that Dr. Mohan served as a senior manager at Eli Lilly and Company. From May 1993 to April 1996, Dr. Mohan served as Assistant Professor (Lecturer/Fellow) at the Advanced Centre for Biochemical Engineering, University College London, London, United Kingdom.

Dr. Mohan received a Doctor of Philosophy in Biochemical Engineering from the School of Chemical Engineering, University of Birmingham, Birmingham, United Kingdom, a master’s in financial management from Middlesex University Business School, London, United Kingdom, and a bachelor’s degree in chemical engineering from the Indian Institute of Technology in Roorkee, India. Dr. Mohan also attended an Executive Management Program (AMP) from Fuqua School of Business at Duke University.

What is Pankaj Mohan's net worth?: The estimated net worth of Pankaj Mohan is at least $72,686.39 as of May 15th, 2023. Dr. Mohan owns 25,151 shares of Sonnet BioTherapeutics stock worth more than $72,686 as of November 21st. This net worth approximation does not reflect any other assets that Dr. Mohan may own. Additionally, Dr. Mohan receives an annual salary of $927,000.00 as CEO at Sonnet BioTherapeutics. Learn More about Pankaj Mohan's net worth.
How old is Pankaj Mohan?: Dr. Mohan is currently 59 years old. There are 5 older executives and no younger executives at Sonnet BioTherapeutics. Learn More on Pankaj Mohan's age.
What is Pankaj Mohan's salary?: As the CEO of Sonnet BioTherapeutics Holdings, Inc., Dr. Mohan earns $927,000.00 per year. Learn More on Pankaj Mohan's salary.
How do I contact Pankaj Mohan?: The corporate mailing address for Dr. Mohan and other Sonnet BioTherapeutics executives is 100 OVERLOOK CENTER SUITE 102, PRINCETON NJ, 08540. Sonnet BioTherapeutics can also be reached via phone at 609-375-2227 and via email at [email protected]. Learn More on Pankaj Mohan's contact information.
Has Pankaj Mohan been buying or selling shares of Sonnet BioTherapeutics?: Pankaj Mohan has not been actively trading shares of Sonnet BioTherapeutics within the last three months. Most recently, on Monday, May 15th, Pankaj Mohan bought 16,890 shares of Sonnet BioTherapeutics stock. The stock was acquired at an average cost of $4.84 per share, with a total value of $81,747.60. Following the completion of the transaction, the chief executive officer now directly owns 25,151 shares of the company's stock, valued at $121,730.84. Learn More on Pankaj Mohan's trading history.
Who are Sonnet BioTherapeutics' active insiders?: Sonnet BioTherapeutics' insider roster includes Richard Kenney (Insider), and Pankaj Mohan (CEO). Learn More on Sonnet BioTherapeutics' active insiders.

Pankaj Mohan Insider Trading History at Sonnet BioTherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/15/2023	Buy	16,890	$4.84	$81,747.60	25,151
6/9/2021	Buy	1,454	$34.10	$49,581.40

Pankaj Mohan Buying and Selling Activity at Sonnet BioTherapeutics

Sonnet BioTherapeutics Company Overview

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

Today's Range

Now: $2.90

$2.88

$3.08

50 Day Range

MA: $3.78

$0.71

$6.71

2 Week Range

Now: $2.90

$2.50

$18.72

Volume

60,789 shs

Average Volume

134,745 shs

Market Capitalization

$1.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52

Democrats Sold Out the American Dream - Are you ready?

From Behind the Markets | Ad